LUNG CANCER: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
The New England Journal of Medicine - November 21, 2019 DOI: 10.1056/NEJMoa1913662
As disclosed at ESMO, osimertinib as upfront therapy delivers 7 months extra survival compared with first generation EGFR inhibitors [OS 38.6 versus 31.8 months] and is better tolerated.
Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing and EGFR T790M resistance mutations. A phase 3 trial compared first-line osimertinib with other EGFR-TKIs in patients with EGFR mutation–positive advanced non–small-cell lung cancer (NSCLC). The trial showed longer progression-free survival with osimertinib than with the comparator EGFR-TKIs (hazard ratio for disease progression or death, 0.46). Data from the final analysis of overall survival have not been reported.
mong patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI. The safety profile for osimertinib was similar to that of the comparator EGFR-TKIs, despite a longer duration of exposure in the osimertinib group. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125. opens in new tab.)